Skip to main content

Table 1 Patient and tumor characteristics (n =1843)

From: Trastuzumab in advanced breast cancer – a decade of experience in Germany

Parameter   Treatment  
Trastuzumab monotherapy Trastuzumab plus chemotherapy Trastuzumab plus endocrine therapy only Total
Number of patients 228 (12%) 1346 (73%) 269 (15%) 1843 (100%)
Age     
 Median (range) [years] 59.8 (31 – 91) 58.8 (21 – 87) 61.8 (31 – 95) 59.5 (21 – 95)
 >65 years 26% 26% 36% 28%
 >70 years 16% 13% 20% 14%
ECOG performance status     
 0 29% 30% 37% 31%
 1 56% 55% 51% 54%
 2 13% 13% 11% 13%
 3-4 2% 2% 1% 2%
Tumor grade     
 G1 2% 3% 5% 3%
 G2 49% 42% 49% 44%
 G3 49% 55% 46% 53%
M1 disease at primary diagnosis 24% 26% 28% 26%
Relapse-free interval, median [years] 2.0 2.2 2.6 2.2
Hormone receptor status*     
 Estrogen-receptor positive 41% 54% 84% 57%
 Progesterone-receptor positive 34% 47% 68% 48%
 At least one positive 44% 58% 87% 61%
Metastatic sites at onset of trastuzumab treatment     
 0 18% 7% 14% 10%
 1 45% 42% 52% 44%
 2 25% 33% 23% 31%
 3 8% 13% 9% 12%
 ≥4 4% 5% 1% 4%
Organ site involvement     
 Liver 34% 45% 25% 41%
 Lung 26% 34% 21% 31%
 Bone 41% 45% 55% 46%
 Central nervous system 8% 5% 2% 5%
 Pleural effusion 9% 12% 9% 11%
 Ascites 1% 2% 1% 1%
 Other 20% 20% 19% 20%
Previous treatment     
 Radiotherapy 68% 63% 67% 64%
 Adjuvant chemotherapy 62% 61% 54% 60%
 Adjuvant endocrine therapy 30% 42% 60% 43%
 Palliative chemotherapy 52% 36% 35% 38%
 Palliative endocrine therapy 19% 28% 51% 30%
 Received anthracycline and taxane 48% 37% 46% 40%
 Received trastuzumab 20% 7% 13% 9%
No. of previous palliative chemotherapy regimens (n =692**)     
 1 53% 56% 63% 57%
 2 20% 24% 21% 23%
 3 14% 10% 9% 11%
 4 12% 8% 5% 8%
LVEF, median (range) [%] 65 (30 – 82) 65 (35 – 95) 65 (40 – 98) 65 (30 – 98)
  1. * unknown in 5% of patients, ** population with palliative cytotoxic pretreatment.
  2. Abbreviations: ECOG Eastern Cooperative Oncology Group, LVEF Left ventricular ejection fraction.